First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3...

Area of Science:

• Oncology
• Clinical Trials
• Immunotherapy

Background:

• The ASTRUM-005 trial indicated survival benefits of serplulimab plus chemotherapy for extensive-stage small cell lung cancer (ES-SCLC).
• Long-term outcomes and safety data were previously limited.

Purpose of the Study:

• To evaluate the extended efficacy, safety, patient-reported outcomes (PROs), and biomarkers of serplulimab combined with chemotherapy in previously untreated ES-SCLC.
• To assess the long-term survival benefit and safety profile of this combination therapy.

Main Methods:

• An international, double-blind, phase 3 randomized clinical trial (ASTRUM-005) involving 585 patients with ES-SCLC.
• Patients received either serplulimab or placebo, combined with carboplatin and etoposide, with a median follow-up of 42.4 months.
• Primary endpoint was overall survival (OS); secondary endpoints included other efficacy measures, safety, and PROs.

Main Results:

• Serplulimab significantly improved median overall survival (15.8 vs 11.1 months) and 4-year survival rates (21.9% vs 7.2%) compared to placebo.
• Grade 3 or higher adverse events were comparable between groups (35.0% vs 29.1%).
• Patient-reported outcomes showed improved overall health, reduced dyspnea and pain, and faster alopecia recovery in the serplulimab group.

Conclusions:

• Extended follow-up confirms long-term survival benefits of adding serplulimab to chemotherapy for ES-SCLC.
• The combination demonstrates a favorable efficacy and safety profile, supporting its role as a first-line standard of care.
• Serplulimab plus chemotherapy represents a significant advancement for patients with previously untreated extensive-stage small cell lung cancer.